The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FMS | +15.73% | -34.16% | -8.01% | +211% |
| S&P | +12.65% | +91.73% | +13.89% | +885% |
Fresenius Medical Care AG & Co. KgaA engages in the provision of products and services for individuals with renal diseases of which regularly undergo dialysis treatment. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the healthcare services business. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Positive trial news for a kidney failure drug could cut into business for dialysis therapies companies such as Fresenius.
The company announced that it will simplify its corporate structure.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $5.71B | 9.2% |
| Gross Profit | $1.45B | 15.3% |
| Gross Margin | 25.43% | 1.4% |
| Market Cap | $15.30B | 22.4% |
| Market Cap / Employee | $0.14M | 25.9% |
| Employees | 109.9K | -2.8% |
| Net Income | $382.52M | 31.9% |
| EBITDA | $1.00B | 27.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.48B | -3.5% |
| Accounts Receivable | $3.81B | 5.2% |
| Inventory | 2.5K | 4.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.97B | 2.8% |
| Short Term Debt | $1.34B | -27.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 2.22% | 0.3% |
| Return On Invested Capital | 3.24% | -0.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $661.03M | -26.2% |
| Operating Free Cash Flow | $872.62M | -18.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 22.76 | 21.94 | 23.28 | 19.11 | 9.23% |
| Price to Book | 0.87 | 0.97 | 1.08 | 0.99 | 18.49% |
| Price to Sales | 0.64 | 0.70 | 0.79 | 0.71 | 18.23% |
| Price to Tangible Book Value | -6.22 | -7.18 | -9.71 | -8.21 | 57.01% |
| Price to Free Cash Flow TTM | 9.12 | 9.90 | 9.53 | 10.19 | 5.69% |
| Enterprise Value to EBITDA | 24.37 | 31.95 | 33.58 | 27.32 | -13.30% |
| Free Cash Flow Yield | 11.0% | 10.1% | 10.5% | 9.8% | -5.39% |
| Return on Equity | 3.9% | 4.4% | 4.7% | 5.3% | 11.54% |
| Total Debt | $11.37B | $11.69B | $12.94B | $12.31B | -1.59% |
No podcast episodes available.
FMS earnings call for the period ending September 30, 2021.
FMS earnings call for the period ending June 30, 2021.
FMS earnings call for the period ending March 31, 2021.
FMS earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
